Takeda and Shionogi to cancel copromotion for Intuniv and Vyvanse products for ADHD in 2023.
Takeda Pharmaceutical and Shionogi will terminate their license agreement for the joint development and commercialization of two ADHD treatments at the end of March 2023
The two products subject to the latest announcement are Intuniv (guanfacine) and Vyvanse (lisdexamfetamine dimesylate). These products have been copromoted by the two companies, but Takeda will be solely responsible for their detailing activities beginning in April 2023.
Shionogi will remain as the products’ marketing authorization (MA) holder for now, but the pair will discuss the timing of their MA transfer as well as distribution operations. The termination comes as Takeda exercised an option to retrieve the full rights to these two medicines, which was specified in a 2011 license pact signed between now-defunct Shire and Shionogi. The decision triggers an undisclosed sum of one-time payment to Shionogi in FY2023.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins